CanSino Biologics Inc.
CASBFOTCHealthcare● Active
$3.97
+$0.97(+32.33%)
Market Cap$1.4B
P/E Ratio—
52W High$6.99
52W Low$3
CanSino Biologics Inc.（CASBF）· 资产负债表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · CASBF · 截至 2026-06-10
财务报表
Total Assets · Total Liabilities · Equity
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & ST Investments | $2.65B | $3.20B | $4.12B | $5.95B | $7.78B |
| Net Receivables | $0.79B | $0.79B | $0.64B | $1.08B | $0.16B |
| Inventory | $0.34B | $0.28B | $0.35B | $0.68B | $0.88B |
| Total Current Assets | $3.84B | $4.28B | $5.18B | $7.73B | $9.29B |
| PP&E Net | $2.71B | $2.66B | $3.01B | $3.08B | $2.22B |
| Goodwill | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Intangible Assets | $0.22B | $0.27B | $0.21B | $0.26B | $0.20B |
| Total Assets | $7.19B | $7.96B | $9.32B | $11.47B | $11.87B |
| Liabilities | |||||
| Short-Term Debt | $0.32B | $0.89B | $1.39B | $1.58B | $1.08B |
| Accounts Payable | $0.05B | $0.06B | $0.10B | $0.25B | $0.84B |
| Total Current Liabilities | $1.08B | $1.77B | $2.59B | $2.94B | $2.87B |
| Long-Term Debt | $0.96B | $1.10B | $1.07B | $0.88B | $0.04B |
| Total Liabilities | $2.05B | $3.05B | $4.03B | $4.22B | $3.33B |
| Stockholders Equity | |||||
| Retained Earnings | ($0.47B) | ($1.94B) | ($1.56B) | $0.04B | $1.03B |
| Total Stockholders Equity | $4.96B | $4.91B | $5.27B | $6.75B | $8.00B |
| Total Liab & Equity(computed) | $7.01B | $7.96B | $9.31B | $10.97B | $11.32B |
| Debt Summary | |||||
| Total Debt | $1.29B | $2.01B | $2.70B | $2.70B | $1.37B |
| Net Debt | $0.05B | $0.46B | $0.65B | ($0.69B) | ($4.08B) |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · CNY · B
深入了解CanSino Biologics Inc.
关于CanSino Biologics Inc.（CASBF）资产负债表
CanSino Biologics Inc.总资产$7.19B，现金及短期投资$2.65B，总负债$2.05B，总债务$1.29B，股东权益$4.96B。
常见问题
CASBF · 4 问CanSino Biologics Inc.总债务$1.29B，净债务$0.05B。
CASBF total debtnet debtdebt to equity
· Source: FMP /stable/balance-sheet-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10